Pro-inflammatory and anti-inflammatory markers in coronary artery disease and acute ischemic coronary syndrome;Marcadores pro y antiinflamatorios en la enfermedad arterial coronaria y el síndrome isquémico coronario agudo

Archivos de Cardiologia de Mexico

Volumn 79, Issue 1, 2009, Pages 54-62

  Fragoso Lona, José Manuel ^a   Ramírez Bello, Julián ^b   Cruz Robles, David ^a   Pérez Méndez, Oscar ^a   De La Peña, Aurora ^a,c   Vargas Alarcón, Gilberto ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Acute coronary syndrome; Coronary artery disease; Cytokines; Inflammation

Indexed keywords

ACUTE PHASE PROTEIN; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; FIBRINOGEN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; PROTEIN C; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; CORRELATIONAL STUDY; DISEASE SEVERITY; EVALUATION; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INTRACARDIAC THROMBOSIS; PROPHYLAXIS; PROTECTION; PROTEIN ANALYSIS; PROTEIN SECRETION; REVIEW; RISK;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CELL ADHESION MOLECULES; CHEMOKINES; CORONARY ARTERY DISEASE; FIBRINOGEN; HUMANS; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-6; MYOCARDIAL ISCHEMIA; SERUM AMYLOID A PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650360977     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J. 2000;21:1574-1583
2. Goran KH. Inflammation, atherosclerosis, and coronary artery disease. N Eng J Med. 2005;352:1685-1695
3. Garcia-Mol X. Inflammatory and anti-inflammatory markers in acute in acute coronary syndromes. Ready for use in the clinical setting? Rev Esp Cardiol. 2005;58:615-617
4. Carter MA. Inflammation, thrombosis and acute coronary syndromes. Diabetes Vase Dis Res. 2005;2:113-121
5. Alexander RW. Inflammation and coronary artery disease. N Engl J Med. 1994;331:468-469
6. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126
7. Montavi A. The interplay between primary and secondary cytokines. Cytokines involved in the regulation of monocyte recruitment. Drugs. 1997;97Suppl:15-23.
8. Castell JV, Andus T, Kunz D, Heinrich PC. Interleukin-6: the major regulator of acute-phase protein synthesis in man and rat. Ann N YAcad Sci. 1989;557:87-101.
9. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454
10. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, et al. Serum level of the anti-inflamatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation. 2003;107:2109-2114
11. Os I, Djurovic S, Seljeflot I, Berg K. Transforming growth factor (TGF)-β1 inversely related to vascular cell adhesion molecule-1 in post menopausal women with coronary artery disease. A possible mechanism for the putative cardioprotective role of TGF-β1? J Intern Med. 2002; 251:223-227
12. Dinarello CA. Biological basis for interleukin-1 in disease. Blood. 1996;87:2095-2147
13. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Eng J Med. 1993;328:106-113
14. Sims JE, March CJ, Cosman D, Widmer MB, MacDonald HR, McMahan CJ. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science. 1988;241:585-589
15. Libby P, Ordovas JM, Birinyi LK, Auger KR, Dinarello CA. Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest. 1986;78:1432-1438
16. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA. Interleukin-1 induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984;160:618-623
17. Lopes-Virella MF. Interactions between bacterial liposaccharides and serum lipoproteins and their possible role in coronary artery disease. Eur Heart J. 1993;14 Suppl K:118-124
18. Hasdai D, Scheinowitz M, Leibovitz E, Sclarovsky S, Aldar M, Barak V. Increased serum concentrations of interleukin-1β in patients with coronary artery disease. Heart. 1996;76:24-28
19. Vohnout B, Di Castelnuovo A, Trotta R, D'Orazio A, Panniteri G, Montali A, et al. Interleukin-1 gene cluster polymorphisms and risk of coronary artery disease. Haematologica. 2003;88:54-60.
20. Saadeddin SM, Habbab MA, Ferns GA. Markers of inflammation and coronary artery disease. Med Sci Monit. 2002;8:RA5-12.
21. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today. 1992;13:151-153
22. Tartaglia LA, Weber RF, Figari IS. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Nat Acad Sci USA. 1991;88:9292-9296
23. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745-756
24. Bemelman MHA, Van Tits LJH, Buurman WA. Tumor necrosis factor: function, release and clearance. Crit Rev Immunol. 1996;16:1-11.
25. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detection and localization of TNF in human atheroma. Am J Cardiol. 1990;65:297-302.
26. Hale KK, Smith CG, Baker SL. Multifunctional regulation of the biological effects of TNF-α by the soluble type I and type II TNF receptors. Cytokine. 1995;7:26-38.
27. Maury CPJ, Teppo AM. Circulating tumor necrosis factor-α (cachectin) in myocardial infarction. J Int Med. 1989;225:333-336
28. Pannitteri G, Marino B, Campa PP, Martucci R, Testa U, Peschle C. Interleukin 6 and 8 as mediators of acute phase response in acute myocardial infarction. Am J Cardiol. 1997;80:622-625
29. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the vesnarinone trial (VEST). Circulation. 2001;103:2055-2059
30. Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, et al. Tumor necrosis factor-α receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction. Circulation. 2005;111:863-870
31. Aggawal BB, Puri RK. Human cytokines: their role in disease and therapy. Cambridge: Blackwell Science Ed.; 1995. p. 3-24.
32. Müller-Newn G, Küster A, Hemman U, Keul R, Horsten U, Marstens A, et al. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. The J Immunol. 1998;161:6347-6355
33. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes. Part I: introduction and cytokines. Circulation. 2006;113:e72-5.
34. Barton BE. The biological effects of interleukin 6. Med Res Rev. 1996;16:87-109.
35. Lotz M. Interleukin-6. Cancer Invest. 1993;11:732-742
36. Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol. 2006;63:321-329
37. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80:227-236
38. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood. 1993;82:1120-1126
39. Martins TB, Anderson JL, Muhlestein JB, Home BD, Carlquist JF, Roberts WL, et al. Risk factor analysis of plasma cytokines in patients with coronary artery disease by a multiplexed fluorescent immunoassay. Am J Clin Pathol. 2006;125:906-913
40. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-1772
41. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and woman. N Engl J Med. 2004;351:2599-2610
42. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary disease. Effects of an early invasive or noninvasive strategy. JAMA. 2001;286:2107-2113
43. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Eng J Med. 1998;338:436-445
44. Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol (Regul Integr Comp Physiol). 2002;283:R7-28.
45. Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol. 2001;2:95-101.
46. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991;88:1121-1127
47. Apostolopoulos J, Davenport P, Tipping PG. Interleukin-8 production by macrophages from atheromatous plaques. Arterioscl Thromb Vasc Biol. 1996;16:1007-1012
48. Taub DD, Proost P, Murphy WJ, Anver M, Longo DL, Van Damme J, et al. Monocyte chemotactic protein-1 (MCP-1) and -3 are chemotactic for human T lymphocytes. J Clin Invest. 1995;95:1370-1376
49. Gerzten RE, García-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999;398:718-723
50. Van der Wal AC, Becker AE, Vander Loos CM, Das PK. Site of intimai rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44.
51. Hansson GK. Cell-mediated immunity in atherosclerosis. Curr Opin Lipidol. 1997;8:301-311
52. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis. 2006;17:699-706.
53. Inoue T, Komoda H, Nonaka M, Kameda M, Uchida T, Node K. Interleukin 8 as an independent predictor of long-term clinical out come in patients with coronary artery disease. Int J Cardiol. 2008;124:319-325
54. Luscinskas FW, Gimbrone MA Jr. Endotelial-dependent mecahnisms of mononuclear leucocyte recruitment. Ann Rev Med. 1996;47:413-421
55. Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Ann Rev Physiol. 1995;57:827-872
56. Jang Y, Lincoff AM, Plow EF. Cell adhesion molecules in coronary artery disease. Am J Coll Cardiol. 1994;24:1591-1601
57. Blann AD, McCollum CM. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost. 1994;72:151-154
58. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103:491-495
59. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risk of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88-92.
60. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89:763-771
61. Hajilooi M, Sanati A, Ahmadieh A, Ghofraniha A, Massoud A. Circulating ICAM-1, VCAM-1, E-selectin, P-selectin, and TNFRII in patients with coronary artery disease. Immunol Invest. 2004;3:263-275
62. O'Malley T, Ludlam CA, Riemermsa RA, Fox KA. Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1). Potential risk factor for the acute coronary syndromes. Eur Heart J. 2001;22:1226-1234
63. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001;104:1336-1342
64. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141-212.
65. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 1999;7:169-177
66. Mackiewicz A, Speroff T, Ganapathi MK, Kushner I: Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol. 1991;146:3032-3037
67. Paffen E, DeMaat MP. C-reactive protein in atherosclerosis: A causal factor? Cardiovasc Res. 2006;71:30-39
68. Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Heart. 2006;92:441-444
69. Amezcua-Guerra LM, Springall del Villar R, Bojalin-Parra R. Proteina C reactiva: aspectos cardiovasculares de una proteina de fase aguda. Arch Cardiol Mex. 2007;77:58-66.
70. Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. Q J Med. 2003;96:793-807.
71. Devaraj S, O'Keefe G, Jialal I. Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J Clin Endocrinol Metab. 2005;90:4549-4554
72. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem. 2001;47:403-411
73. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265:501-523
74. Urieli-Shoval S, Cohen P, Einserberg S, Matzner Y. Widespread expression of serum amyloid A in histological normal human tissues: predominant localization to the epithelium. J Histochem Cytochem. 1998;46:1377-1384
75. Meek RI, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Nat Acad Sci USA. 1994;91:3186-3190
76. Yamada T, Kakihara T, Kamishima T, Fukuda T, Kawai T. Both acute phase and constitutive serum amyloid A are present in atherosclerotic lesions. Phatol Int. 1996;46:797-800.
77. Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo. The association of C-reactive protein, serum amyloid A and fibrinogen with prevalent coronary heart disease-baseline findings of PAIS project. Atherosclerosis. 2001;156:451-456
78. Chait A, Han CY, Oram JF, Heinecke JH. Lipoprotein-associated inflammatory protein: markers or mediator of cardiovascular disease? J Lipid Res. 2005;46:389-403.
79. Malle E, De Beer FC. Human serum amyloid (SAA) protein: a prominent acute phase reactant for clinical practice. Eur J Clin Invest. 1996;36:427-435
80. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et al. Serum amyloid A predicts early mortality in acute coronary syndromes. A TIMI 11A substudy. J Am Coll Cardiol. 2000;35:358-362
81. Doolittle RF, Spraggon G, Everse SJ. Three-dimentional structure studies of fragments of fibrinogen and fibrin. Curr Opin Struct Biol. 1998;8:792-798
82. Haidaris PJ, Francis CW, Sporn LA, Arvan DS, Collichio FA, Marder VJ. Megakaryocyte and hepatocyte origins of human fibrinogen biosyntesis exhibit hepatocyte-specific expression of gamma chain variant polypeptides. Blood. 1989;74:743-750
83. Kamath S, Lip GYH. Fibrinogen: biochemistry, epidemiology and determinants. QJ Med. 2003;96:711-729
84. Miyao Y, Yasue H, Ogawa H, Misumi I, Masuda T, Sakamoto T, et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J. 1993;126:1299-1304
85. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor. Ann Inten Med. 1993;118:263-269
86. Coppola G, Rizzo M, Abrignani MG, Corrado E, Di Girolamo A, Braschi A, et al. [Fibrinogen as a predictor of mortality after acute myocardial infarction: a forty-two-month follow-up study]. Ital Heart. 2005;6:315-322
87. Becker R, Cannon C, Bovill E. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q ware infarction enrolled in the TIMI III trial. Am J Cardiol. 1996;78:142-147
88. Blankerberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, et al. Interleukin-18 and the risk of coronary heart disease in European men: the prospective epidemiological study of myocardial infarction (PRIME). Circulation. 2003;108:2453-2459
89. Waehre T, Halvorsen B, Damas JK, Yndestad A, Brosstad F, Gullestad L, et al. Inflammatory imbalance between IL-10 and TNF-alpha in unstable angina potential plaque stabiling effects of IL-10. Eur J Clin Invest. 2002;32:803-810
90. Girndt M, Köhler H. Interleukin-10 (IL-10): an update on its relevance for cardiovascular risk. Nephrol Dial Transplant. 2003;18:1976-1979
91. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflamatory cytokine interleukin-10 are decreased in patients with unstable angine. Circulation. 2001;104:746-749
92. Fichtlscherer S, Breuer S, Heeschen C, Dimmeler S, Zeiher AM. Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease. J Am Coll Cardiol. 2004;44:44-49
93. Gunnett CA, Heistad DD, Berg DJ, Faraci FM. IL-10 deficiency increases superoxide and endothelial dysfunction during inflammation. Am J Physiol Heart Circ Physiol. 2000;279:H1555-62.
94. Mostafa Mtairag E, Chollet-Martin S, Oudghiri M, Laquay N, Jacob MP, Michel JB, et al. Effects of interleukin-10 on monocyte/endothelial cell adhesion and MMP-9/TIMP-1 secretion. Cardiovasc Res. 2001;49:882-890
95. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest. 1995;96:2304-2310
96. Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor β in human disease. N Engl J Med. 2000;342:1350-1358
97. Morisaki N, Kawano M, Koyama N, Koshikawa T, Umemiya K, Saito Y, et al. Effects of transforming growth factor β1 on growth of aortic smooth muscle cells. Atherosclerosis. 1991;88:227-234
98. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, et al. The serum concentration of active transforming growth factor β is severely depressed in advanced atherosclerosis. Nat Med. 1995;1:74-79
99. Stefoni S, Cianciolo G, Donati G, Dormi A, Silvestri GM, Coli L, et al. Low TGF-β1 serum levels are a risk factor for atheroclerosis disease in ESRD patients. Kidney Int. 2002;61:324-335
100. Wang XL, Liu SX, Wilcken DE: Circulating transforming growth factor beta 1 and coronary artery disease. Cardiovasc Res. 1997;34:404-410
101. Dabek J, Kulach A, Monastyrska-Cup B, Gasior Z. Transforming growth factor β and cardiovascular disease: the other facet of the "protective cytokine". Pharmacol Rev. 2006;58:799-805.